For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Scope of the Report:
This report focuses on the Drugs for Vulvovaginal Candidiasis in North America market, especially in United States, Canada and Mexico. This report categorizes the market based on manufacturers, countries, type and application.
Market Segment by Manufacturers, this report covers
- J & J
- Bristol-Myers Squibb
- Cisen Pharmaceutical
- Kingyork Group
Market Segment by Countries, covering
Market Segment by Type, covers
- Hospital & Clinic
Market Segment by Applications, can be divided into
- Hospital & Clinic
There are 15 Chapters to deeply display the North America Drugs for Vulvovaginal Candidiasis market.
Chapter 1, to describe Drugs for Vulvovaginal Candidiasis Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force;
Chapter 2, to analyze the manufacturers of Drugs for Vulvovaginal Candidiasis, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;
Chapter 4, to show the North America market by countries, covering United States, Canada and Mexico, with sales, revenue and market share of Drugs for Vulvovaginal Candidiasis, for each country, from 2013 to 2018;
Chapter 5 and 6, to show the market by type and application, with sales, price, revenue, market share and growth rate by type, application, from 2013 to 2018;
Chapter 7, 8 and 9, to analyze the segment market in United States, Canada and Mexico, by manufacturers, type and application, with sales, price, revenue and market share by manufacturers, types and applications;
Chapter 10, Drugs for Vulvovaginal Candidiasis market forecast, by countries, type and application, with sales, price and revenue, from 2018 to 2023;
Chapter 11, to analyze the manufacturing cost, key raw materials and manufacturing process etc.
Chapter 12, to analyze the industrial chain, sourcing strategy and downstream end users (buyers);
Chapter 13, to describe sales channel, distributors, traders, dealers etc.
Chapter 14 and 15, to describe Drugs for Vulvovaginal Candidiasis Research Findings and Conclusion, Appendix, methodology and data source